Caroline Seymour

January 07, 2023

A combined regimen of mitazalimab and mFOLFIRINOX resulted in a 52% objective response rate among 23 patients with metastatic pancreatic cancer.

December 29, 2022

In the PEARL trial, monotherapy with durvalumab did not deliver a statistically significant improvement in overall survival vs platinum-based chemotherapy as frontline treatment in patients with PD-L1-high stage IV non–small cell lung cancer.

November 05, 2022

After 13.1 months of follow-up, the median progression-free survival in patients with EGFR-mutant non–small cell lung cancer who received a sintilimab-based regimen was 5.5 months.

October 28, 2022

A presentation at the 2022 ESMO Congress found that xevinapant plus chemoradiotherapy decreased the risk of death by twice that of placebo for patients with unresectable, locally advanced head and neck squamous cell carcinoma.

October 18, 2022

An analysis of patient-reported outcomes showed that patients with advanced ovarian cancer experienced fewer abdominal or gastrointestinal toxicities with mirvetuximab soravtansine than with chemotherapy.

October 16, 2022

Phase 2 findings indicate that a combination of avelumab and axitinib may draw promising responses in patients with advanced type B3 thymoma and thymic carcinoma.

October 15, 2022

A subgroup of the phase 3 GLOW trial revealed a unique relationship between undetectable minimal residual disease status and progression-free survival in elderly or unfit patients with chronic lymphocytic leukemia who received ibrutinib plus venetoclax.

October 12, 2022

Tivozanib, an oral VEGF inhibitor, improved overall survival in patients with relapsed or refractory, advanced renal cell carcinoma.

September 04, 2022

At a median follow-up of 22.9 months, patients with platinum-refractory metastatic urothelial carcinoma achieved a median overall survival of 14.6 months with EphB4-human serum albumin plus pembrolizumab.

August 24, 2022

Rucaparib may be a viable maintenance therapy option for patients with DNA repair–deficient positive, metastatic urothelial cancer who are unlikely to benefit from avelumab immunotherapy.